Candel Therapeutics Inc [CADL] stock prices are down -12.15% to $8.75 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CADL shares have gain 29.63% over the last week, with a monthly amount glided 119.85%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Candel Therapeutics Inc [NASDAQ: CADL] stock has seen the most recent analyst activity on December 02, 2022, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $11. Previously, BMO Capital Markets started tracking the stock with Outperform rating on November 19, 2021, and set its price target to $18. On August 23, 2021, UBS initiated with a Buy rating and assigned a price target of $9 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $22 on August 23, 2021. Credit Suisse initiated its recommendation with a Outperform and recommended $15 as its price target on August 23, 2021.
The stock price of Candel Therapeutics Inc [CADL] has been fluctuating between $1.02 and $14.60 over the past year. Candel Therapeutics Inc [NASDAQ: CADL] shares were valued at $8.75 at the most recent close of the market.
Analyzing the CADL fundamentals
Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -20.02%, Pretax Profit Margin comes in at -29.39%, and Net Profit Margin reading is -29.39%. To continue investigating profitability, this company’s Return on Assets is posted at -2.43, Equity is 32.1 and Total Capital is -5.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.00 points at the first support level, and at 7.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.75, and for the 2nd resistance point, it is at 10.75.
Ratios To Look Out For
It’s worth pointing out that Candel Therapeutics Inc [NASDAQ:CADL]’s Current Ratio is 1.18. On the other hand, the Quick Ratio is 1.18, and the Cash Ratio is 1.08.
Transactions by insiders
Recent insider trading involved Manning Paul B, Director, that happened on Dec 16 ’24 when 1.25 million shares were purchased. Chief Technology Officer, Tyagarajan Seshu completed a deal on Nov 29 ’24 to sell 20392.0 shares. Meanwhile, Chief Executive Officer Tak Paul Peter sold 48847.0 shares on Nov 29 ’24.
